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ABSTRACT: The wound infections caused by bacteria and fungi are a significant problem in healthcare. 
Therefore, an effective treatment and prevention seems to be essential. Povidone-iodine is one of the 
commercial antimicrobial agents used for skin disinfection, in surgery and for local anti-infective treatment. 
The broad activity spectrum of this compound includes numerous species of Gram-positive and Gram-
negative bacteria, mycobacteria, fungi, protozoa and viruses. Povidone-iodine is recommended for acute 
wounds as well as lacerations, bruises and deep wounds due to its good tissue penetration. 
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1. INTRODUCTION 
Bacteria are a part of the physiologic skin and mucous membranes flora and in that way wounds [1]. 
Additionally, non-pathogenic or potentially pathogenic microorganisms of transient flora reside the skin and 
mucous membranes for hours to weeks [2]. Exceeding the critical threshold of 105 bacteria (critical 
colonization) may cause an infection. Additionally, antibiotic-resistant strains can significantly impede wound 
healing [1]. 
Most chronic wounds comprise more than one bacterial species. Among them Staphylococcus aureus, 
S. epidermidis, Streptococcus agalactiae, Enterococcus faecalis, Corynebacterium spp., Pseudomonas 
aeruginosa, Stenotrophomonas maltophilia, Acinetobacter baumannii, Escherichia coli, Proteus mirabilis, 
Serratia spp., Finegoldia magna, Propionibacterium acnes, Fusobacterium nucleatum, Prevotella spp., and 
Bacteroides fragilis are the most often. An increase in surgical site infections (SSIs) correlated with 
methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. aureus were observed. Infections caused 
by fungi, such as Candida albicans and C. glabrata are also a significant problem. Moreover, Pseudomonas 
aeruginosa, Staphylococcus epidermidis, and Staphylococcus aureus are capable to form biofilms that 
contribute to antibiotic resistance [2-4]. 
To reduce the risk of infection, antiseptic agents are used. Antiseptics are naturally occurring or 
synthetic organic substances intended for local, topical use, that destroy or inhibit the growth of 
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microorganisms on skin, mucous membranes or damaged tissue [4]. One of the commercial antimicrobial 
agent is the polyvinylpyrrolidone–iodine (povidone-iodine, PVP-I). 
PVP-I was introduced in 1956 [5] and its routinely used as a preparation for skin disinfection in 
combination with alcohol and intraoperatively as a dilute solution. Its efficacy against wide variety of Gram-
positive and Gram-negative bacteria, fungi, protozoa, viruses, good tolerability and lack of resistance suggests 
the correctness of use PVP-I in wound healing and infection prevention [6-9]. 
2. CHEMICAL ASPECTS 
Povidone-iodine is a yellowish-brown chemical complex of 1-ethenylpyrrolidin-2-one and molecular 
iodine with a slight characteristic odor. The iodine content is from 9.0 to 12.0% (calculated on a dry basis). 
The substance has a molecular formula C6H9I2NO and a molecular weight 364.95 g/mol [10]. Figure 1 shows 
the chemical structure of the compound. 
 
 
Figure 1. Chemical structure of povidone-iodine. 
 
The solubility of PVP-I at water and alcohol is good and it is practically insoluble in acetone, 
chloroform, light petroleum or carbon tetrachloride. There are available different concentrations of PVP-I 
used depending on the purpose: as a 10%, 7.5%, 5%, 1.28%, 1% and also 0.45% formulation (as a throat 
spray) [10, 11].The 10% commercial formulation is composed of 90% water, 8.5% povidone and 1% iodine 
and iodide [12, 13]. 
Mixing povidone and iodine indicates a chemical reaction. It is considered that iodine is complexed by 
polyvinylpyrrolidone and iodide through a hydrogen bond between two pyrroles. As a result, povidone-iodine 
exists with a small amount of free iodine. It has been documented that exposure to organic substances like 
whole blood, pus or fat reduces a bactericidal activity of PVP-I. It is most likely caused by iodine complexing 
and chemical reactions, such as the reduction to iodide. Moreover, approximately 46 to 59 mg of iodine is 
bound by one gram of hemoglobin [6]. In addition, it is worth remembering that in chronic wounds, iodine 
compounds should not be combined with silver-containing dressings, also due to the precipitation of iodides 
[4]. 
3. MODE OF ACTION 
The microbicidal activity of PVP-I is based on release the free iodine to the solution from the PVP-I 
complex. PVP provides iodine to cells membranes, but itself has no biocidal properties. There has been 
demonstrated the paradoxical behavior of substance; in contrast to other iodine preparations, the content of 
free iodine primitively increases with the increasing dilution, reaching a maximum value at about 0.1% 
formulation and decreasing on further dilution [14]. This translates into antimicrobial activity of                 
compound [7]. 
The iodine effects on amino, thiol and phenolic hydroxyl groups of amino acids and nucleotides in 
biological structures. Additionally, iodine reacts with the double bonds of unsaturated fatty acids in the cell 
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wall and membranes of organelles [15]. This mode of action leads to disruption of pathogens metabolic 
pathways and irreversible damage of the cell membranes structural components. PVP-I also inhibits the 
production and secrete of bacterial exotoxins [3, 11, 16]. 
The virucidal mechanism of action is based on the inhibition of essential viral enzymes. The 
inactivation of neuraminidase prevents viral release from the host cell, making a further spread of the virus to 
uninfected cells impossible. Haemagglutinin is also inhibited by iodophor and attachment to host cell receptor 
is blocked [17]. 
4. ANTIMICROBIAL ACTIVITY 
PVP-I has a broad spectrum of antimicrobial activity even after a short time of exposition [7]. It 
demonstrates efficacy against Gram-positive, Gram-negative, various spore-forming bacteria (Clostridium 
spp., Bacillus spp.), mycobacteria and also enveloped and non-enveloped viruses [8, 18]. Equally inactivation 
of antibiotic sensitive and resistant staphylococci and enterococci, such as methicillin-resistant 
Staphylococcus aureus and Enterococcus faecalis, by PVP-I was demonstrated [19-22]. Also Gram-negative 
bacteria, including Pseudomonas aeruginosa and Escherichia coli presented sensitivity on PVP-I [17, 20, 23]. 
Minimal inhibitory concentrations (MIC) of PVP-I against some bacterial and fungal species are presented in 
Table 1. 
Biofilms impede wound healing and increase resistance to antibiotics. Studies have shown the in vitro 
efficacious of PVP-I against S. epidermidis, S. aureus and Candida albicans growth, as well as the inhibition 
biofilm formation [8]. Moreover, the iodophor revealed fungicidal activity against Candida auris [24], 
Aspergillus flavus and Cryptococcus neoformans [6]. 
 
Table 1. MICs (minimal inhibitory concentrations) of PVP-I against bacterial and fungal species. 
Species MIC (µg/mL) References 
Staphylococcus aureus 0.24-512 [3, 25, 26] 
Methicillin-resistant S. aureus (MRSA) 7.81-5210 [9, 25, 27] 
S. epidermidis 781-5000 [28, 29] 
Streptococcus pyogenes 490-4688 [9, 27] 
Escherichia coli 4-1024 [25, 26, 30] 
Carbapenem-resistant E. coli (CREC) 4-128 [30] 
Klebsiella pneumoniae 4-64 [30] 
Carbapenem-resistant K. pneumoniae (CRKP) 8-128 [9, 30] 
Pseudomonas aeruginosa 125-8330 [3, 27] 
Chlamydia trachomatis 97-1562 [9, 31] 
Bacteroides fragilis 3130-4688 [9, 27] 
Candida albicans 256-5000 [25, 32, 33]  
C. glabrata 10-5000 [32, 33] 
Cryptococcus sp. 2500 [32] 
 
Viruses and chlamydia play a meaningful role in infections. PVP solutions indicate high effective 
against Herpes simplex virus and excellent efficacy against the enveloped influenza A virus. Adenovirus type 
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8 proved to be sensitive to PVP-I, although, contrary to Herpes simplex, a longer time of exposure was 
necessary to inactivation. Enteroviruses and Coxsackievirus were resistant to povidone-iodine [7, 17]. 
5. APPLICATION 
PVP-I has a wide range of applications. In 2014, European Chemicals Agency approved PVP-I as an 
existing active substance for use in biocidal products for types 1, 3, 4, and 22 (human hygiene, veterinary 
hygiene, food and feed area, and embalming and taxidermist fluids) [9]. Efficacy of wound infection 
treatment, prophylactic intraoperative wound irrigation, hand wash preparations, skin disinfection and topical 
antiseptic has been shown [13, 34-37]. Povidone-iodine is available in a pre- and postoperative skin 
desinfection [38, 39]. 
PVP-I as an antiseptic formulation is the first choice for stab, bite and gunshot wounds [3]. In difficult-
to-heal wounds (including chronic wounds), it is not recommended due to its cytotoxicity, limitations of use, 
and the incompatibility between PVP-I and the silver-based dressings [40]. It is also useful in the care of 
surgical wounds, and in wounds such as the diabetic foot, as it can be used to rinse deep wounds with lack 
drainage [41-43]. The use of PVP-I as a vaginal antiseptic has also been demonstrated. Presurgical vaginal 
irrigation with PVP-I significantly reduces the risk of post-cesarean endometritis, wound infections and 
pyrexia in patients who underwent cesarean delivery [44, 45]. 
Some studies indicate that PVP-I formulations are effective in eradication pathogenic cultures of the 
external auditory canal after tympanoplasty [46], in intraocular injection, ophthalmic surgery, also as a 
cataract surgery [12], in treating the corneal ulcers [47] or preventing post-cystoscopy urinary tract infection 
(UTI) [48]. Moreover, PVP-I is used for mucosal antisepsis, in oral surgery and dental conditions [11]. 
Studies present the positive effects of PVP-I gargles/mouthwashes against Bordetella pertussis, Klebsiella 
pneumoniae and Streptococcus pneumoniae strains [18, 49]. 
However, an equally important factor conditioning the proper healing process is the low cytotoxicity of 
the antiseptic. The Biocompatibility Index (BI) may be helpful in choosing the right preparation (Table 2).  
 
Tabela 2. Biocompatibility index as a quotient of IC50 for L929 cells and the required MIC for a reduction factor                          
of ≥3 log10 [40]. 
Compound Escherichia coli Staphylococcus aureus 
Octenidine 1,7 2,1 
PHMB 1,5 1,4 
PVP-I (aqueous solution, referring on I2) 0,9 1,0 
Chlorhexidine 0,7 0,7 
Triclosan 0,2 0,5 
Ag-protein (referring on Ag+) 0,2 0,1 
Ag(I)-sulfadiazine and silver nitrate not measurable 
 
The BI value >1 indicates that a given product has a broad spectrum against microorganisms and a low 
level of cytotoxicity against fibroblasts or keratinocytes, and therefore its use does not adversely affect the 
healing process. It is also important that the antiseptic preparation has a high degree of penetration through 
biofilm structures, does not induce resistance build-up, and does not cause incompatibility with other 
substances contained in dressings and has the ability to prolonged operation (residua effect). Currently, in 
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clinical practice, the most frequently chosen antispetics for the prevention and treatment of chronic wounds 
are octenidine and iodine-containing agents (such as iodine povidone) [4, 40, 50]. 
Sometimes, sensitizations against PVP-I cross-reacts to iodinated contrast media. However, these can 
be detected by a simple skin test. In addition, PVP-I allergies are relatively rare [8]. Hypersensitivity to the 
povidone-iodine, hyperthyroidism, toxic nodular goiter, herpes dermatitis syndrome, radioactive iodine 
therapy and peritoneal lavage are contraindications to povidone-iodine usage. Application during pregnancy 
and breastfeeding, as well as in patients under 12 years old is not recommended [3, 51]. 
6. CONCLUSION 
Povidone-iodine is a relatively inexpensive antimicrobial agent characterized by a broad spectrum of 
activity, efficacy against biofilms and no resistance. Additionally, rapid action and good tolerability confirm 
the appropriateness of using PVP-I formulations in the clinical treatment of surgical wounds and the 
prevention of infections. PVP-I may help reduce the wound healing period and shorten the hospitalization as 
well as reduce treatment costs. 
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